



Veterans Affairs Updated Guidance on Patient Selection Criteria for Continuous Glucose Monitors¹

WHAT'S NEW?

Documentation of Justification for CGM:

Providers prescribing CGM devices for Veterans must confirm and document the Veteran has diabetes and is being treated with daily insulin. Veterans receiving insulin daily are eligible for a CGM device. It is recommended that CGM be considered under the following circumstances:

- a. Veterans who require **daily insulin** to achieve desired glycemic management targets and/or avoid hypoglycemia based on shared decision-making, as recommended by the VA/DoD Clinical Practice Guideline Management of Diabetes Mellitus.
- b. Veterans with uncommon conditions in which **hypoglycemia is a significant concern** (for example, post-gastrectomy, paraneoplastic syndromes, reactive hypoglycemia) may be considered on a case-by-case basis by the Endocrinology subject matter expert at the VISN or facility.

Requesting CGM Devices:

An order for a CGM device should be made to **Prosthetics** by the independent practitioner/consultant team who will be responsible for the Veteran's clinical management. The order should reference a progress note justifying the specific medical indication, the Veteran's individual circumstances indicating the need for a CGM, the Veteran's ability to use the device, and a plan for clinical follow-up. Services meeting this requirement include Endocrinology, Pharmacy, Primary Care, and other services with experience in the use of CGMs as designated by the facility/Veterans Integrated Service Network.



Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply. Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

1. Memorandum, Updated Guidance on Patient Selection Criteria for Continuous Glucose Monitors (CGM), July 7, 2023- Department of Veterans Affairs.

Important Safety Information:

Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or <https://www.FreeStyle.abbott/us-en/safety-information.html> for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.

© 2023 Abbott. ADC-61060 v2.0